The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple-negative breast cancer clinical development and clinical outcome

Autor: Xiong, Y., Ismail-Khan, R., Abbasi, F., Bou Zgheib, N., Ramirez, I., Bush, S., Hakam, A., Judson Lancaster, P.L., Lancaster, J.M.
Zdroj: In Gynecologic Oncology June 2014 133 Supplement 1:61-61
Databáze: ScienceDirect
Externí odkaz: